DEF: TG Therapeutics 2026 Proxy Statement Overview

TG Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 11, 2026, at 9:30 a.m. ET via live webcast.
• Stockholders will vote on the election of six directors, the ratification of KPMG LLP as the independent auditor for 2026, and an advisory vote on executive compensation.
• The record date for voting is April 14, 2026, with 153,093,879 shares of common stock outstanding.
• The company reported 2025 full-year global revenue of $616.3 million, driven by BRIUMVI commercialization.
• Executive compensation for 2025 included a 131% achievement level for corporate goals, with no discretionary adjustments applied.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a stable filing reflecting strong commercial execution, though the lower-than-average say-on-pay support suggests some shareholder friction regarding executive pay levels.

Positives

• BRIUMVI U.S. net product revenue reached $594.1 million for 2025, a 92% year-over-year growth.
• Successful expansion of BRIUMVI commercialization into the EU, UK, Switzerland, Australia, Kuwait, and the UAE.
• Strong pay-for-performance alignment with 131% achievement of corporate goals and no discretionary payout increases.
• Significant portion of executive compensation is at-risk and tied to long-term performance metrics.
• The company successfully completed patient enrollment for key Phase 3 pivotal programs.

Negatives

• The 2025 say-on-pay advisory vote received only 54.3% approval, indicating mixed stockholder sentiment regarding executive compensation.
• The company remains obligated under a long-term office lease agreement in New York City, despite subleasing the space to a third party.

Risks

• Potential for competitive harm if specific performance metrics for corporate goals are disclosed.
• Reliance on a small number of key executive officers for strategic leadership.
• Risks associated with the highly competitive and regulated biopharmaceutical industry.
• Exposure to potential excise taxes under Section 4999 of the Code in the event of a change in control.

Future Outlook

The company continues to focus on the commercialization of BRIUMVI, the advancement of its clinical pipeline including subcutaneous ublituximab, and the evaluation of azer-cel for autoimmune diseases.

Management Comments

• The Compensation Committee believes that 2025 compensation outcomes were strongly aligned with Company performance.
• The Board believes that having a director who is an executive officer serve as the Chairman is in the best interest of the Company's stockholders at this time.

Industry Context

StockSavvy.ai notes that TG Therapeutics is operating in a highly competitive anti-CD20 monoclonal antibody market, with its compensation structure heavily weighted toward long-term performance to retain leadership during a critical commercial growth phase.

Comparison to Industry Standards

• The company's board size is smaller than many peers, resulting in lower aggregate director compensation costs.
• The 2025 peer group was updated to include 17 commercial-stage biopharmaceutical companies to better reflect the company's current scale and complexity.
• The company's pay-for-performance model aligns with standard industry practices for high-growth biotech firms.

Corporate Governance

Related Party Transactions

• The company maintains an Office Agreement with Fortress Biotech, Inc. (FBIO) for shared office space, with an estimated average annual rental obligation of $1.8 million.
• The company has a Shared Services Agreement with FBIO for shared personnel and administrative costs, incurring $1.2 million in expenses in 2025.

Stakeholder Impact

• Shareholders are asked to vote on director elections and executive compensation.
• Employees benefit from the 401(k) match program and equity incentive plans.
• The company's commercial success directly impacts its ability to fund future clinical development.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 11, 2026.
• Conduct the advisory vote on executive compensation.
• Ratify the appointment of KPMG LLP as the independent registered public accounting firm for 2026.

Key Dates

Recommendation

The company is showing strong commercial growth, but the high executive compensation packages and mixed shareholder support for pay-on-pay suggest a cautious approach for institutional investors.

Keywords

TG Therapeutics, TGTX, Proxy Statement, BRIUMVI, Biotechnology, Executive Compensation, Corporate Governance